Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses surgical cytoreduction in ovarian cancer.

With recently emerging data, oncologists are better equipped to identify patients who do not need primary cytroreduction. Additionally, Leath says that oncologists now know what to do—and what not to do&mdash;at the time of surgery for their patients with ovarian cancer.

Videos

Dr. Leath Discusses Surgical Cytoreduction in Ovarian Cancer

Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses ongoing trials for patients with endometrial cancer.

Endometrial cancer is the most common gynecologic cancer, explains Leath. However, there is a lot that is unknown regarding the ideal treatment for endometrial cancer.

The PORTEC-3 and GOG 258 compared chemotherapy with various approaches of chemoradiation therapy. Standard chemotherapy has been beneficial; however, the role of radiation needs to be investigated further, states Leath.

Charles A. (Trey) Leath III, MD

Articles

Dr. Leath Discusses Surgical Cytoreduction in Ovarian Cancer

Dr. Leath on Ongoing Trials for Endometrial Cancer